A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07502417
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Ethinyl Estradiol + Levonorgestrel — DRUG
    Oral
  • ABBV-722 — DRUG
    Oral

Study Details

The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of ethinyl estradiol and levonorgestrel.

Key Dates

Start date
Mar 27, 2026
Status verified
Apr 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
16 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Period 1 & 2
    In Period 1, participants will receive a single dose of ethinyl estradiol and levonorgestrel. In Period 2, participants will receive multiple daily doses of ABBV-722 and a single dose of ethinyl estradiol and levonorgestrel.

Primary Outcome Measure

Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol and Levonorgestrel [ Time Frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 281745GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site
Acpru· Grayslake, IL

Related Studies